Healthcare & Life Sciences

PulseSight Therapeutics SAS

Francepulsesight.com/2026/05/11/positive-results-from-pulsesights-phase-i-clinical-trial-of-pst-611-in-dry-amd-geographic-atrophy-presented-at-arvo-2026/
alive
Sign in to unlockWebsite

About

PulseSight Therapeutics SAS is a clinical-stage biotech company developing non-viral vectorized gene therapies delivered via minimally-invasive electro-transfection technology for treating retinal diseases, primarily focusing on age-related macular degeneration including geographic atrophy.

Explore PulseSight Therapeutics SAS's full profile on Brouky

Funding rounds, investor list, and risk signals — unlock with a subscription.

Sign in to unlockView pricing